JB/CALL/GILEAD SCIENCES/90/0.05/21.03.25

JB/CALL/GILEAD SCIENCES/90/0.05/21.03.25 Share Price

GIZQJB

CH1303724632

Market Closed - Bid/Ask 16:20:00 26/06/2024 BST			After market 16:15:00
0.06 ^CHF	-14.29%		0.055	-8.33%

3 months	-45.45%
6 months	-72.73%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart JB/CALL/GILEAD SCIENCES/90/0.05/21.03.25

Latest news about GILEAD SCIENCES, INC.

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	06-27	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	06-26	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	06-25	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	06-24	MT

More news

Quotes 5-day view

Date	Price	Change
26/06/24	0.06	-14.29%
25/06/24	0.07	-12.50%
24/06/24	0.08	+14.29%
21/06/24	0.07	+75.00%

Delayed Quote Swiss Exchange

Last update June 26, 2024 at 04:20 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Bank Julius Bär
	GIZQJB
ISIN	CH1303724632
Date issued	23/11/2023
Strike	90 $
Maturity	21/03/2025 (266 Days)
Parity	20 : 1
Emission price	0.17 CHF
Emission volume	N/A
Settlement	Barausgleich
Currency	CHF

Technical Indicators

Highest since issue	0.37 CHF
Lowest since issue	0.02 CHF
Spread	0.01 CHF
Spread %	16.67%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

68.83 USD

Average target price

82.97 USD

Spread / Average Target

+20.54%

Consensus